Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 plus SOX vs placebo plus SOX in resectable gastric or gastroesophageal junction cancer
CTR20212838Phase 3Terminated
- Sponsor
- Suzhou Sundia Biotech Co., Ltd.
- Start
- Nov 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of retlirafusp alfa in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Suzhou Sundia Biotech Co., Ltd.. Started Nov 2021; status: terminated.
02
Drugs
retlirafusp alfa
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20212838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212838.